{"title":"作为大规模杀伤性癌症武器的 CARD11-PIK3R3 T 细胞疗法。","authors":"Wanlu Zhang, Min Wu, Yongye Huang","doi":"10.1002/mco2.628","DOIUrl":null,"url":null,"abstract":"<p>Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11–PIK3R3, to increase activator protein 1 and nuclear factor–κB signaling, interleukin-2 production, and tumor death in vitro and in vivo\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":null,"pages":null},"PeriodicalIF":10.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215281/pdf/","citationCount":"0","resultStr":"{\"title\":\"Engineered CARD11–PIK3R3 T-cell therapies as weapons of cancer mass destruction\",\"authors\":\"Wanlu Zhang, Min Wu, Yongye Huang\",\"doi\":\"10.1002/mco2.628\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11–PIK3R3, to increase activator protein 1 and nuclear factor–κB signaling, interleukin-2 production, and tumor death in vitro and in vivo\\n\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure>.</p>\",\"PeriodicalId\":94133,\"journal\":{\"name\":\"MedComm\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":10.7000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215281/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mco2.628\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedComm","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mco2.628","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
Garcia 等人发现了一种新的免疫疗法方法，通过对治疗用 T 细胞中自然发生的突变进行工程改造，从而大大提高了抗肿瘤活性。作者发现了一种基因融合物 CARD11-PIK3R3，它能在体外和体内增加激活蛋白 1 和核因子-κB 信号、白细胞介素-2 的产生以及肿瘤的死亡。
Engineered CARD11–PIK3R3 T-cell therapies as weapons of cancer mass destruction
Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11–PIK3R3, to increase activator protein 1 and nuclear factor–κB signaling, interleukin-2 production, and tumor death in vitro and in vivo
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
